Financial Daily from THE HINDU group of publications
Wednesday, Apr 28, 2004

Cross Currency

Group Sites

Home Page - Pharmaceuticals
Corporate - Announcements

Ranbaxy gets FDA clearance for hypertension drug

Our Bureau

New Delhi , April 27

RANBAXY Laboratories has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Fosinopril Sodium tablets in 10 mg, 20 mg, and 40 mg strengths used mainly for treatment of hypertension.

The Office of Generic Drugs, USFDA, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug, Bristol Myers Squibb Company's Monopril tablets 10 mg, 20 mg, and 40 mg, respectively.

The total sales for Fosinopril Sodium tablets last year stood at $267 million.

Fosinopril is also indicated in the management of heart failure as adjunctive therapy when added to conventional therapy.

In a statement, Mr Jim Meehan, Vice-President (Sales and Marketing), Ranbaxy Pharmaceuticals Inc, said: "We will begin shipping immediately and will be able to provide this product to our distribution customers in a matter of days. Subsequently, this affordable, generic alternative will have a positive economic impact that will benefit the US healthcare system and patients."

More Stories on : Pharmaceuticals | Announcements | Regulatory Bodies & Rulings

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
`Star struck' MFs look to team-based initiatives

Ranbaxy gets FDA clearance for hypertension drug
Infosys to pay freshers better
Oilseed prices at 10-year high in global market on lower crop
Rupee drops, G-secs down
Sensex sinks on poll forecast — Loses 213 in heaviest fall in 3 years
Broadband norms to be released tomorrow

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line